Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omalizumab for improving pregnancy rates in women with asthma undergoing IVF/ICSI
2018-001137-41Phase 2Completed
- Sponsor
- Copenhagen University Hospital - Hvidovre
- Start
- Apr 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in infertility and asthma comparing Omalizumab with Placebo (2 arms). Primary endpoints: Pregnancy rate (birth or loss of pregnancy after three consecutive IVF cycles) and Ultrasound-confirmed pregnancy at week 7. Started Apr 2018; status: completed.
02
Drugs
omalizumab
03
Conditions
infertilityasthma
Beyond the preview
Go deeper on 2018-001137-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001137-41.